Ardelyx is a biopharmaceutical company focused on medicines for cardiorenal and gastrointestinal conditions. Its commercial products include tenapanor (IBSRELA) for irritable bowel syndrome with constipation and XPHOZAH for controlling serum phosphorus in adults with chronic kidney disease on dialysis. The company develops and markets therapies aimed at specialists treating kidney disease and GI disorders.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 74.1 | — | -41.1 | — |
| Q2 2025 | 97.7 | — | -19.1 | — |
| Q3 2025 | 110.3 | — | -1 | — |
| Q4 2025 | 125.2 | — | -0.4 | — |
| Q1 2026 | 94.5 | 27.5% | -37.6 | — |
| Q2 2026 | 120.9 | 23.8% | -16.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Service Properties Trust (SVC), Alumis Inc. (ALMS), Kelly Services, Inc. (KELYB), Independent Bank Corporation (IBCP), Barrett Business Services, Inc. (BBSI), Mako Mining Corp. (MAKO)